Significant Accounting Policies - Potentially dilutive securities outstanding (Details) - shares |
6 Months Ended | ||
|---|---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
Sep. 30, 2019 |
|
| Significant Accounting Policies | |||
| Common stock purchase options | 6,506,966 | 3,337,406 | 6,375,966 |
| Unvested restricted stock | 3,125 | 1,433,472 | 6,875 |
| Common stock purchase warrants | 715,939 | 101,847 | 728,439 |
| Convertible notes | 0 | 638,138 | |
| Antidilutive securities excluded from computation of earnings per share | 7,226,030 | 5,510,863 | |
| X | ||||||||||
- Definition Number of convertible notes excluded from the computation of diluted weighted average shares outstanding. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|